AI at the Point of Care
AI in Veterinary Diagnostics · Installation 1 of 6
There is a particular kind of frustration that comes with receiving a biopsy that was not ideally sampled — or reviewing a case where the clinical context provided is a single sentence. The tissue might tell part of the story. The rest lives in decisions that were made, or not made, before the sample ever left the clinic.
That is where artificial intelligence stands the most immediate chance of making a difference in veterinary medicine. Not in replacing the diagnostic expertise at the end of the pipeline, but in improving the quality of what enters it.
This isn't new — human medicine has been here first
It is worth starting with what is already happening in human medicine, because the foundational technology driving AI diagnostics in veterinary practice is the same technology that has been reshaping human clinical workflows for the better part of a decade.
AI-assisted decision support tools have been in active use in human emergency departments and primary care settings for years — flagging sepsis risk, surfacing differential diagnoses, and flagging imaging findings for radiologist review. AI-assisted dermoscopy tools have been validated against dermatologist performance for melanoma detection. Large language models are being evaluated in clinical triage settings to help prioritize patient acuity and ensure relevant differentials are not overlooked.
None of these tools replaced the physician. What they did was reduce the cognitive burden at moments of high complexity and low available time — precisely the conditions that characterize a busy veterinary practice. The same underlying AI capabilities that power those human clinical tools are now being applied to veterinary medicine. That translation is neither automatic nor trivial, but the foundation is real and well-established.
Context from human medicine
AI diagnostic support tools are already embedded in major human health systems — from sepsis prediction algorithms in ICUs to AI-assisted radiology flagging in community hospitals. The transition to veterinary medicine does not require proving the technology works. It requires proving the veterinary-specific implementation is sound.
The front end of the diagnostic process is where information is most fragile
A diagnosis is only as good as the information feeding into it. In veterinary practice, the front end of that process — the moment a clinician is standing in the exam room, weighing a differential list, deciding what to sample and how — is also where information is most easily lost. Clinical pattern recognition is the most sophisticated tool in any clinician's kit. But pattern recognition is fatigable, context-dependent, and highly variable across experience levels.
AI-assisted decision support is not an attempt to replicate that pattern recognition wholesale. The more realistic and more useful aim is to serve as a structured cognitive scaffold — prompting consideration of differentials, flagging gaps in the clinical picture, and surfacing possibilities that might not be top of mind in a busy practice setting.
What decision support is not: A diagnostic AI tool is not a diagnosis. It does not examine the patient. It does not replace the clinical assessment of an experienced veterinarian. What it can do is organize, prompt, and structure — reducing the likelihood that an important differential is overlooked or that a sample is submitted without adequate clinical context.
Harnessing existing AI — with veterinary oversight built in
Here is something that often gets lost in how AI diagnostic tools are marketed: the underlying AI capabilities powering most of these tools already exist. Large language models can already generate plausible differential lists. Image recognition models can already identify surface-level morphologic features in a photograph. The raw capability is not the hard part.
The hard part is ensuring that capability is applied correctly in a veterinary diagnostic context — and that is precisely where unsupervised AI falls short. Without species-specific clinical logic, an AI differential tool will apply human or canine prevalence assumptions indiscriminately. Without an understanding of how lesion morphology maps to histopathologic pattern in a given tissue type, image-based suggestions can be misleading. Without knowledge of how diagnostic sensitivity and specificity shift between species, a well-intentioned tool can send a clinician in the wrong direction. Like an experienced clinician who has learned to be watchful of what they don't know, an AI system operating without specialist oversight doesn't know what it doesn't know.
The tools being developed under the Vetopathy platform are built on these existing AI capabilities — but structured, constrained, and developed with veterinary pathologist oversight at their core. PathIQ by Vetopathy harnesses AI-driven differential generation, but its clinical logic is grounded in species-specific diagnostic reasoning developed and continuously refined with input from board-certified veterinary pathologists. The goal is not to add a layer of branding over a generic AI tool. It is to make the AI's output less likely to be wrong in the ways that matter most to veterinary clinicians — and to the pathologist reviewing what gets submitted.
That distinction — AI capability shaped by specialist oversight — is what separates a veterinary diagnostic tool from a general-purpose model that happens to know the word "lymphoma."
Gross lesion recognition: closing the submission gap
A related and underappreciated problem is the quality of gross lesion documentation at submission. Pathologists depend on clinical context. A biopsy accompanied by a photograph that captures lesion morphology, distribution, and tissue character provides substantially more interpretive leverage than one submitted with "skin mass, left flank."
AI-assisted gross image analysis is an emerging category of tool attempting to close this gap. A clinician captures a clinical photograph, and the AI analyzes it for morphologic features — surface character, shape, color change, distribution — to help frame what is being submitted and what the most likely diagnostic categories are.
PathView by Vetopathy is being developed in this space. It uses image analysis to generate a morphology-informed differential list at the point of submission, with the intent of improving both the clinical narrative accompanying a biopsy and the clinician's pre-histopathologic reasoning. The same principles apply: its value lies in the combination of AI image capability with species-specific logic developed and reviewed by veterinary pathologists — not in image recognition alone.
Why specialist oversight reduces risk: General-purpose AI models are trained on broad datasets that skew heavily toward human medicine and common domestic species. They produce confident-sounding output regardless of whether their training data supports it in a given context. A framework built with veterinary pathologist input introduces species-specific guard rails, adjusts differential weighting by prevalence, and catches the category of errors a generic model would never flag — because it doesn't know what it doesn't know.
Where this is headed — and what to watch for
The near-term trajectory of AI in point-of-care veterinary diagnostics is less about dramatic capability leaps and more about thoughtful integration. The most impactful tools will be those that fit inside existing clinic workflows without requiring a behavioral overhaul — tools that meet the clinician at the moment of decision rather than adding a separate step.
Closed-loop integration between decision support tools and diagnostic submission platforms is a logical endpoint: a system where the differential reasoning that happened in the exam room is preserved and transmitted alongside the sample, so the pathologist can interpret not just the tissue but the full clinical context in which it was collected.
There are also meaningful open questions. Veterinary-specific validation of AI diagnostic tools is sparse across the board. Species diversity adds complexity that human medicine AI tools simply do not face. And the risk of over-reliance — the erosion of clinical judgment that can follow from any decision-support tool — is real and worth naming plainly.
None of that means the tools emerging in this space aren't valuable. It means they should be adopted with appropriate skepticism, with clear-eyed attention to what they have and have not been shown to do — and with preference for tools built with specialist oversight, not just impressive-sounding AI output.
Next in this series: AI and the diagnostic sample — how artificial intelligence is beginning to influence cytology interpretation, biopsy site selection, and what gets submitted in the first place.